Sichuan Biokin Pharmaceutical Co Ltd banner
S

Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506

Watchlist Manager
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Watchlist
Price: 273 CNY -4.05% Market Closed
Market Cap: ¥112.7B

EV/S

49.3
Current
0%
Cheaper
vs 3-y average of 49.5

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
49.3
=
Enterprise Value
¥116.6B
/
Revenue
¥2.2B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
49.3
=
Enterprise Value
¥116.6B
/
Revenue
¥2.2B

Valuation Scenarios

Sichuan Biokin Pharmaceutical Co Ltd is trading below its 3-year average

If EV/S returns to its 3-Year Average (49.5), the stock would be worth ¥274.1 (0% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-93%
Maximum Upside
+0%
Average Downside
46%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 49.3 ¥273
0%
3-Year Average 49.5 ¥274.1
+0%
5-Year Average 49.5 ¥274.1
+0%
Industry Average 3.5 ¥19.31
-93%
Country Average 3.3 ¥18.27
-93%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
¥116.6B
/
Oct 2025
¥2.2B
=
49.3
Current
¥116.6B
/
Dec 2025
¥2.2B
=
54.2
Forward
¥116.6B
/
Dec 2026
¥2.1B
=
56.7
Forward
¥116.6B
/
Dec 2027
¥2.6B
=
45.4
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
CN
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
112.7B CNY 49.3 -132.2
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 12.8 39
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 5.9 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.7 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 5.1 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 5.1 19.5
US
Merck & Co Inc
NYSE:MRK
274.6B USD 4.7 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD 108.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 11.1
US
Pfizer Inc
NYSE:PFE
150.6B USD 3.2 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 3.1 16.4
P/E Multiple
Earnings Growth PEG
CN
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Average P/E: 21.5
Negative Multiple: -132.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.5
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1

Market Distribution

Higher than 98% of companies in China
Percentile
98th
Based on 7 593 companies
98th percentile
49.3
Low
0 — 1.7
Typical Range
1.7 — 6.2
High
6.2 —
Distribution Statistics
China
Min 0
30th Percentile 1.7
Median 3.3
70th Percentile 6.2
Max 5 034 353.9

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
112.7B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
24.65 CNY
Overvaluation 91%
Intrinsic Value
Price ¥273
S
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett